Based on the more encouraging and effective results of multi clinical trials, many countries have adopted ICIs (PD-1/PDL-1 inhibitor) combined with chemotherapy as the first-line treatment for ES-SCLC and included it in the relevant treatment guidelines (11, 21). This evidence concerns the gene CD274 and small cell lung carcinoma.